New test helps determine prostate cancer outcome:
This article was originally published in Clinica
Measuring the ratio of free-floating prostate specific antigen (PSA) to total PSA in the blood could help doctors determine a patient's prognosis following radiotherapy for prostate cancer, according to a Canadian study. Researchers studied 102 men undergoing prostate biopsy around 40 months after radiotherapy for prostate cancer. Their results, published in the July issue of Urology, showed that the ratio of free to total PSA was on average significantly lower in those with positive biopsies (15%) compared with those who had negative biopsies (27%).
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.